scispace - formally typeset
H

Hiroaki Shimokawa

Researcher at Tohoku University

Publications -  976
Citations -  56856

Hiroaki Shimokawa is an academic researcher from Tohoku University. The author has contributed to research in topics: Heart failure & Endothelium. The author has an hindex of 111, co-authored 949 publications receiving 48822 citations. Previous affiliations of Hiroaki Shimokawa include University of Nebraska Medical Center & Nagoya University.

Papers
More filters
Journal ArticleDOI

Increased Reactive Oxygen Species in Rostral Ventrolateral Medulla Contribute to Neural Mechanisms of Hypertension in Stroke-Prone Spontaneously Hypertensive Rats

TL;DR: Results suggest that superoxide anions in the RVLM, which generate hydroxyl radicals, are increased inSHRSP and contribute to the neural mechanisms of hypertension in SHRSP.
Journal ArticleDOI

Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.

TL;DR: PTPA is a promising therapeutic option for distal-type CTEPH, which markedly improved pulmonary hemodynamics and pulmonary artery structure, as confirmed by angiography and optical coherence tomography.
Journal ArticleDOI

Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries.

TL;DR: In this article, the authors examined whether H(2)O(2)-derived hyperpolarizing factor (EDHF) is a primary EDHF in human mesenteric arteries with some contribution of gap junctions.
Journal ArticleDOI

Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension.

TL;DR: The Rho/Rho-kinasepathway plays an important role in regulation of vascular smooth muscle cell (VSMC) contraction and other cellular functions such as proliferation and migration.
Journal ArticleDOI

Heart failure as a general pandemic in Asia.

TL;DR: Information regarding the current and future burden of HF in Asia indicates the importance of both primary prevention of underlying diseases of HF and secondary prevention, including management of ischaemic HF, HF with preserved EF, and HF in the elderly.